BRCA2 and ovarian cancer: Utilising this data, as well as mortality figures of ovarian cancer in pathogenic BRCA1/2 carriers, mortality is reduced 4.7-fold for BRCA1, and 46-fold for BRCA2. All calculations are demonstrated in Tables 3 and 4 for BRCA1 and BRCA2 respectively, and were based on the following assumptions: everyone will have had a prophylactic oophorectomy, patients have the same survival benefit as the documented literature, and all P/LP variants behave the same way.